CompletedPhase 2NCT03636347

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Mereo BioPharma
Principal Investigator: Robert Stockley, Prof.
University of Birmingham
Intervention: Placebo Oral Tablet(drug)
Enrollment: 99 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2018 – 2022

Study locations (26)

University of Alabama, Birmingham (UAB), Birmingham, Alabama, United States
UCLA Medical Center, Los Angeles, California, United States
UC Davis Medical Centre, Sacramento, California, United States
PMG Research of Wilmington, Wilmington, North Carolina, United States
UZ Gent, Ghent, Belgium
UZ Leuven, Leuven, Belgium
The University Lung Clinic, Edmonton, Alberta, Canada
Centre for Heart Lung Innovation, St Pauls Hospital, Vancouver, British Columbia, Canada
Inspiration Research Ltd, Toronto, Ontario, Canada
University of Saskatchewan Royal University Hospital, Saskatoon, Saskatchewan, Canada
Aarhus Universitetshospital, Aarhus, Denmark
Gentofte Hospital, Hellerup, Denmark
Synddansk Universitet (SDU) - Odense University, Odense, Denmark
Instytut Gruzilicy Chorob Pluc, Warsaw, Poland
Hospital Univ Clinico San Carlos, Madrid, Spain
+11 more locations on ClinicalTrials.gov

Collaborators

Syneos Health

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03636347 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency →

← Back to all trials